The earliest sign of DN is the development of microalbuminuria which is associated with a significant risk of both progressive renal failure and premature death from cardiovascular disease. Optimal glycaemic and BP control, including the use of RAAS blocking drugs, can prevent, slow and even reverse the processes causing DN.
|Number of pages||5|
|Journal||Clinical medicine (London, England)|
|Publication status||Published - Oct 2010|
ASJC Scopus subject areas